Oncology

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
Friday, March 22, 2024
MYGN, Diagnosis, Genetic testing, Patent, Combinatorics, Genetics, Patient, Neoplasm, Research, DNA, Myriad Genetics, Doctor of Philosophy, Oncology, Medicine, University, MD Anderson Cancer Center, MRD, Intellectual property, FDA, Estate (law), Pharmaceutical industry

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Employment, Development, ARVN, PROTAC, Pfizer, Oncology, Partnership, Novartis, Executive, Patient, Knowledge, National Cancer Institute, Bristol Myers Squibb, BMS, Neuroscience, Columbia University, LRRK2, Pharmaceutical industry

Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.

Key Points: 
  • Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
  • “We are thrilled to have Dr. Berkowitz join Arvinas as we continue advancing multiple programs with the goal of improving the lives of patients with serious diseases,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology.
  • The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers, Accepted for Presentation at the 2024 ESMO Sarcoma and Rare Cancers Congres

Retrieved on: 
Thursday, March 14, 2024
Malignancy, Congress, Oncology, Sarcoma, Cancer, Therapy, Poster

Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against cancers with well-established IGF-1R pathway involvement, including malignancies with known genetic alterations affecting the IGF-1R pathway and/or with high IGF-1R expression.

Key Points: 
  • Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against cancers with well-established IGF-1R pathway involvement, including malignancies with known genetic alterations affecting the IGF-1R pathway and/or with high IGF-1R expression.
  • The poster is available on the Lirum website ( www.lirumtx.com ) under the Investors and Media tab.
  • Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway.
  • Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Concept, Plasma, Candidate, RECIST, Oncology, RAS, Patient, FACP, City, Cancer, Pancreatic cancer, Neoplasm, Therapy, Safety, Pharmacokinetics, SLD, Pharmaceutical industry

“Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Key Points: 
  • “Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.
  • Immuneering evaluated both 240mg and 320mg QD as prospective doses for the Phase 2a portion of its Phase 1/2a study.
  • The Phase 2a portion is expected to include up to twenty clinical sites and has already dosed its first patient.
  • Initial data from multiple arms of the Phase 2a portion of Immuneering’s Phase 1/2a study of IMM-1-104 expected in 2024.

Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go

Retrieved on: 
Tuesday, March 12, 2024
Documentation, ECOG, Disease, Patient, SAN, Eastern Cooperative Oncology Group, NLP, Assessment and plan, Oncology, Ambulatory care, Electronic health record, A&P, Heart, HPI, Assessment, Collection

SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced new positive data and product enhancements for Augmedix Go , its ambient AI medical documentation product.

Key Points: 
  • SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced new positive data and product enhancements for Augmedix Go , its ambient AI medical documentation product.
  • Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients.
  • Additionally, 94% of clinicians surveyed reported that Augmedix Go helps them better focus on their patients.
  • By utilizing multiple models that cross-check each other, Augmedix is delivering high quality notes that instill trust among clinicians.

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Harvard College, Health, Internal medicine, Public health, Disease, Atossa, Oncology, Patient, Cornell University, Weill Cornell Medical Center, Woman, Helsinki University Central Hospital, Clinical trial, Therapy, Breast cancer, Hematology, Weill Cornell Medicine, Pharmaceutical industry

Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.

Key Points: 
  • Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.
  • “We are pleased to welcome Dr. Cigler to our board of directors,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer.
  • “Tessa works daily with breast cancer patients and knows firsthand the critical need for more effective and tolerable treatment options.
  • While progress has been made over the past decade, breast cancer remains a deadly disease for hundreds of thousands of women globally each year.

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.

PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors

Retrieved on: 
Friday, April 5, 2024
Oncology, Medical Devices, Health, Surgery, Clinical Trials, Biotechnology, Boston University, Toxicity, Hematology, Genetics, Executive, Monoclonal antibody, Shire (pharmaceutical company), Merck, Acquisition, BMS, Cancer, University, Doctor of Philosophy, Panther, MBA, Marketing, Neoplasm, Therapy, Chemical engineering, Genetics Institute, F-star, FDA, Pharmaceutical industry

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.

Key Points: 
  • PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
  • “John has been an outstanding addition to our Board and management team since joining the company in September.
  • His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
  • During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.

United States Clinical Oncology Next Generation Sequencing Market Research Report 2023-2028: Data Analysis and Interpretation Tools to Streamline Processes and Growth in Genomic Medicine - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Genetics, Health, Oncology, Lifestyle, Theft, Genomics, Growth, Prevalence, Disease, Data analysis, Incidence, Risk, Patient, NGS, Health care, Cancer, Risk assessment, Laboratory, Quality of life, Medicine, Confidentiality, Identity theft, HIPAA, Interpretation, Treatment, Investment, Privacy, Medical imaging

United States Clinical Oncology Next Generation Sequencing Market is anticipated to project robust growth in the forecast period.

Key Points: 
  • United States Clinical Oncology Next Generation Sequencing Market is anticipated to project robust growth in the forecast period.
  • The United States Clinical Oncology Next Generation Sequencing (NGS) market is a dynamic and rapidly evolving sector within the broader healthcare and life sciences industry.
  • The United States is a global leader in clinical oncology NGS, with numerous academic institutions, research centers, and biotechnology companies actively engaged in cutting-edge research and development.
  • Additionally, data analysis tools that adhere to standardized formats promote collaboration, knowledge exchange, and innovation in clinical oncology.

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Retrieved on: 
Saturday, April 6, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology

Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.

Key Points: 
  • Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
  • T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®.
  • The median time to onset of myeloid neoplasms was 447 days (range: 56 to 870 days) after treatment with CARVYKTI®.
  • T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®.